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Glutaric	acidemia	type	I	(GA-I) is	an	inherited	disorder	of	lysine	and	tryptophan	metabolism	presenting	with	
striatal	lesions	anatomically	and	symptomatically	similar	to	Huntington	disease.	Affected	children	commonly	
suffer	acute	brain	injury	in	the	context	of	a	catabolic	state	associated	with	nonspecific	illness.	The	mechanisms	
underlying	injury	and	age-dependent	susceptibility	have	been	unknown,	and	lack	of	a	diagnostic	marker	her-
alding	brain	injury	has	impeded	intervention	efforts.	Using	a	mouse	model	of	GA-I,	we	show	that	pathologic	
events	began	in	the	neuronal	compartment	while	enhanced	lysine	accumulation	in	the	immature	brain	allowed	
increased	glutaric	acid	production	resulting	in	age-dependent	injury.	Glutamate	and	GABA	depletion	cor-
related	with	brain	glutaric	acid	accumulation	and	could	be	monitored	in	vivo	by	proton	nuclear	magnetic	
resonance	(1H	NMR)	spectroscopy	as	a	diagnostic	marker.	Blocking	brain	lysine	uptake	reduced	glutaric	acid	
levels	and	brain	injury.	These	findings	provide	what	we	believe	are	new	monitoring	and	treatment	strategies	
that	may	translate	for	use	in	human	GA-I.
Introduction
Glutaryl-CoA dehydrogenase (EC 1.3.99.7) (GCDH) activity is 
required for complete oxidation of lysine and tryptophan. Autoso-
mal recessive inheritance of GCDH deficiency, known as glutaric aci-
demia type I (GA-I), is one of the more common inherited metabolic 
disorders affecting 1 out of 30,000–100,000 children worldwide (1, 2). 
GA-I results in accumulation of glutaric acid and glutarylcarnitine 
with carnitine deficiency (3–5). Affected individuals accumulate 
substantial glutaric acid in the brain and 3-hydroxyglutaric acid 
(3-OHGA) to a lesser extent (6–8). Following a period of normal devel-
opment, affected children may experience irreversible striatal injury 
during an encephalopathic crisis, commonly precipitated by a non-
specific illness between 6 and 18 months of age (2). The neuropathol-
ogy associated with GA-I is similar to that of Huntington disease, in 
which a systemic genetic defect results in specific striatal degeneration 
involving loss of medium spiny neurons and astrogliosis (6–10).
Current therapy for GA-I includes dietary lysine restriction, 
carnitine supplementation, and emergency treatment of intercur-
rent illness including intravenous glucose (3–5). Unfortunately, 
one-third of affected children, prospectively identified by new-
born screening, do not respond to therapy and experience striatal 
degeneration despite careful clinical management (11). Children 
with GA-I who escape encephalopathy in their first 5 years typi-
cally remain asymptomatic (2). We recently developed an animal 
model of GA-I encephalopathy in GCDH-deficient (Gcdh–/–) mice 
by introducing added dietary protein or lysine (12). This model 
shows age-dependent susceptibility to acute brain injury similar 
to human GA-I. Weanling (4-week-old) Gcdh–/– mice accumulate 
substantial glutaric acid and suffer seizures, paralysis, hemor-
rhages, and death within 3–6 days of lysine diet exposure. In con-
trast, adult (8-week-old) Gcdh–/– mice survive lysine exposure and 
accumulate less glutaric acid, though all develop bilateral striatal 
lesions after 6 weeks of lysine diet exposure.
In the current study, we first localized the origin of brain injury by 
identifying the cell type or types in the brain that express Gcdh and 
the earliest pathological events after protein and lysine supplemen-
tation in weanling Gcdh–/– mice. We then compared the biochemical 
responses in weanling and adult Gcdh–/– mice after lysine diet chal-
lenge to identify differences associated with age-dependent suscep-
tibility. Our current findings identified developmental differences 
that control glutaric acid accumulation and age-dependent brain 
injury. Brain injury was preceded by biochemical changes that 
may be used as a diagnostic marker. These findings led to what we 
believe are novel monitoring and treatment strategies.
Results
Expression pattern of Gcdh predicts neuronal origin of pathologic events in 
the brain. To better understand the mechanism of brain injury, we 
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used double-label immunohistochemistry to determine whether 
Gcdh expression is limited to neurons, astrocytes, or endothelial 
cells. We then used electron and confocal microscopy to detect the 
earliest pathologic events in the brain after special diet exposure. 
Sections of motor cortex and CA1 hippocampus from Gcdh–/+ mice 
revealed that Gcdh expression was limited to neurons (indicated by 
β-gal labeling; see Methods) (Figure 1, A–F).
Pathologic changes were limited to 
Gcdh–/– mice and were evident within 
24–48 hours of protein or lysine diet 
exposure in weanlings (Figure 2, 
A–H). Moderately vacuolated neu-
rons were found in the motor cortex 
with pathological changes previ-
ously associated with necrosis (13) 
(Figure 2E). Dendritic processes in 
the motor cortex showed moder-
ately enlarged mitochondria and 
disorganization of neurofilaments 
(Figure 2F). Swollen and disinte-
grating mitochondria were found in 
postsynaptic regions with edema of 
dendritic spines (Figure 2G), resem-
bling excitotoxic lesions (9). Similar 
changes, though less severe, were 
found in adult Gcdh–/– mice after 60 
hours (Figures 2H and 3B). Although 
adult Gcdh–/– mice do not show obvi-
ous behavioral differences (12), fur-
ther testing may reveal deficits asso-
ciated with these pathologic changes 
after long-term diet exposure.
To confirm the cell types associat-
ed with vacuoles in a larger field, we 
compared confocal images of neu-
rofilament- and astrocyte-labeled 
sections with semithin sections 
prepared for electron microscopy 
(Figure 3, A–D). The vacuoles that 
formed in and around the pyramidal cell layer of CA3 hippocam-
pus (Figure 3B) were surrounded by neurofilaments (shown by 
N52 labeling), indicating a neuronal origin of the vacuoles (Fig-
ure 3D). Vacuolation of astrocytes (glial fibrillary acidic protein 
[GFAP]) was not apparent. Additionally, labeling of cholinergic 
neurons showed vacuole formation in the cell bodies and process-
es of these large neurons of the striatum within 48 hours of lysine 
Figure 1
Neuronal localization of Gcdh expression (β-gal). Motor cortex of WT 
(A) and Gcdh–/+ mouse (B) shows positive β-gal (green) staining colo-
calizes (yellow) with neurons (red) in layer V and VI of Gcdh–/+ mouse 
and not WT by immunofluorescence confocal microscopy. CA1 hippo-
campus from WT (C) and Gcdh–/+ mouse (D) shows positive β-gal stain-
ing for Gcdh–/+ mouse neurons only, similar to that found in motor cor-
tex. Arrows indicate color change. (E) Average projection of 10 confocal 
slices through the CA1 hippocampus of a Gcdh–/+ mouse shows no 
β-gal staining in endothelial cells (thin arrow) or astrocytes (red) (thick 
arrows). (F) A single slice through the CA1 hippocampus shows that 
nuclei associated with astrocytes (thick arrows) and endothelial cells 
(thin arrow) do not stain positive for β-gal while large nuclei of neurons 
are positively stained. β-Gal labeling is nuclear due to nuclear localizing 
sequence; see Methods. (A–D) β-Gal, green; NeuN, red; colocalization 
β-gal and NeuN, yellow; and DAPI, blue. Scale bars: 10 μm. (E and F) 
β-Gal, green; GFAP, red; and DAPI, blue. Scale bars: 10 μm.
Figure 2
Ultrastructural changes after special diet exposure in Gcdh–/– mice. Electron micrographs of motor cor-
tex from weanling (4w) WT (A and B) and Gcdh–/+ (C and D) mice after 60 hours of protein diet show 
normal appearance including dendritic spines (white arrows) and mitochondria (black arrows). (E–G) 
Similar sections from weanling Gcdh–/– mouse motor cortex after 24 hours of protein diet shows vacu-
olated neuron (E, thick arrows) identified by synapse (E, thin arrow, inset) and peripheral chromatin 
aggregation in the nucleus. (F) A large vacuole is noted (*) adjacent to an edematous dendrite, identi-
fied by synapse (white arrow) with disintegrating mitochondrion (black arrow). (G) Higher magnification 
of section similar to that in F shows postsynaptic (white arrows) swelling with enlarged and disrupted 
mitochondrion (black arrow). (H) Similar section from adult (8w) Gcdh–/– mouse cortex shows vacuole 
formation after 60 hours of protein diet exposure. Scale bars: 1 μm.
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diet exposure in weanling Gcdh–/– mice (Figure 3G). These changes 
were less noticeable in adults after 60 hours (Figure 3H).
Brain lysine accumulation and age-dependent susceptibility. To deter-
mine the mechanism of age-dependent susceptibility to encepha-
lopathy in Gcdh deficiency, we considered that brain glutaric acid 
levels were previously shown to correlate with severity of disease 
presentation (12). Therefore, we considered the possibilities that 
(a) brain lysine catabolism, which produces glutaric acid, may be 
reduced with age; (b) brain lysine uptake may be reduced with age; 
or (c) clearance of glutaric acid from the brain may be enhanced 
with age. Based on recent findings that showed limited blood-
brain barrier (BBB) permeability for glutaric acid (14), we pursued 
the first 2 possibilities.
We first tested for differences in brain lysine and glutaric acid 
accumulation between susceptible weanling Gcdh–/– mice and 
encephalopathy-resistant adults. Since there were no significant 
differences between WT and heterozygotes with and without lysine 
diet exposure, we report these changes compared with heterozygous 
controls. All mice accumulated similar serum lysine levels with 
lysine diet exposure (P < 0.01) regardless of age or genotype (Figure 
4A). Brain lysine levels were 46% higher in weanling Gcdh–/– mice 
compared with heterozygous controls, both of which were on 
a normal diet (P < 0.01) consistent with disrupted lysine catabo-
lism in Gcdh–/– mice (Figure 4A). Lysine diet exposure raised brain 
lysine levels by 66% in weanling heterozygotes (P < 0.01) without 
any increase in glutaric acid levels (Figure 4A). Weanling but not 
adult Gcdh–/– mice showed a 3-fold increase in brain lysine accumu-
lation (P < 0.001) accompanied by a 2-fold increase in glutaric acid 
(P < 0.01) after 48 hours of 
lysine diet exposure (Fig-
ure 4A). Between 48 and 60 
hours, a decrease in brain 
lysine was accompanied 
by an equimolar increase 
in glutaric acid, suggest-
ing production of glutaric 
acid within the brain from 
available lysine (Figure 4A). 
At 8 weeks of age, adult 
Gcdh–/– mice showed no 
increase in brain lysine or 
glutaric acid levels on the 
lysine diet, consistent with 
a substantial reduction in 
brain lysine uptake with 
maturity. Changes in brain 
3-OHGA paralleled those 
of glutaric acid although 
3-OHGA concentrations 
were 20-fold lower than 
glutaric acid levels (not 
shown). Although symp-
toms of encephalopathy 
were less evident at the ear-
lier time points examined 
in the current work, brain 
glutaric acid levels correlate 
with acute injury of symp-
tomatic mice as previously 
shown (12).
To determine whether lysine diet exposure had any effect on 
other basic or neutral amino acids, we compared serum and brain 
alanine and arginine levels. Both serum arginine and alanine lev-
els were 2-fold higher only in weanling Gcdh–/– mice on the lysine 
diet (P < 0.01) (Figure 4B). On a normal diet, brain arginine levels 
were 2-fold higher in weanling Gcdh–/– mice compared with het-
erozygotes (P < 0.01) (Figure 4B). Lysine diet exposure raised brain 
arginine 60% in both heterozygotes and weanling Gcdh–/– mice but 
not adults (P < 0.01 and P < 0.001 respectively, compared with het-
erozygote normal diet controls) (Figure 4B). Brain alanine levels 
were unaffected by lysine diet exposure in all groups (Figure 4B). 
These data are consistent with increased flux of the basic amino 
acid transporter in the immature brain that carries both lysine 
and arginine (15).
Serum amino acid accumulation, other than lysine, suggested 
that the lysine diet may induce catabolic stress in weanlings (16). 
Therefore, we measured serum glucose levels and β-hydroxybutyr-
ate as an indicator of serum ketone bodies. Weanling Gcdh–/– mice 
on a normal diet had 27% lower serum glucose levels compared 
with heterozygotes (P < 0.01), which were reduced to less than half 
with lysine diet exposure (P < 0.001) (Figure 4C). Adult Gcdh–/– 
mice also had reduced serum glucose levels with lysine diet expo-
sure compared with heterozygotes (P < 0.01) (Figure 4C). Serum 
β-hydroxybutyrate levels were 30% lower in weanling Gcdh–/– mice 
on a normal diet compared with heterozygous controls (P < 0.01) 
although lysine diet exposure raised β-hydroxybutyrate levels 
almost 4-fold in weanling Gcdh–/– mice and only about 40% in 
weanling heterozygotes (P < 0.001 and P < 0.01 respectively) (Fig-
Figure 3
Neuronal vacuolation after special diet exposure in Gcdh–/– mice. (A) Semi-thin section of WT mouse CA3 hip-
pocampus after 60 hours of protein diet shows normal appearance. (B) Similar section of adult Gcdh–/– mouse 
after 60 hours of protein diet shows a few vacuoles (black arrows). (C) A similar section from a weanling Gcdh–/– 
mouse after 48 hours of protein diet shows multiple vacuoles. (D) Confocal image of a section similar to that 
shown in C labeled with N52, GFAP, and DAPI shows vacuoles surrounded by N52 signal indicating neurofila-
ments (white arrows). (E–H) Acetylcholine transferase–positive neurons in the striatum of a weanling WT mouse 
(E) and weanling Gcdh–/+ mouse (F) after 60 hours of lysine diet exposure show normal appearance. Develop-
ment of vacuoles is prominent within the perikaryon and neuronal processes of a weanling Gcdh–/– mouse (white 
arrows) after 48 hours of lysine diet exposure (G) and less prominent in adult Gcdh–/– mouse after 60 hours (H). 
(D) N52, green; GFAP, red; and DAPI, blue. (E–H) ChAT, red; and DAPI, blue.
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ure 4C). These changes are consistent with induction of catabolic 
stress after lysine diet exposure. Additionally, the reduced serum 
glucose with increased serum alanine levels may represent an 
impairment of gluconeogenesis (16).
Increased brain glutaric acid accumulation in weanling Gcdh–/– 
mice was associated with 20% 12-day survival compared with 100% 
survival of adults on the lysine diet (Figure 4D). Weanlings showed 
brain swelling by MRI at 48 hours and development of bilateral 
striatal lesions at 6 days on the lysine diet (Figure 4E). Together, 
these data indicate that enhanced lysine uptake in the immature 
brain provides increased glutaric acid accumulation and suscepti-
bility to brain injury.
Brain biochemical changes consistent with disrupted mitochondrial func-
tion. Mitochondrial swelling and disruption in the brain of Gcdh–/– 
mice indicate disrupted mitochondrial function with lysine diet 
exposure. Gcdh deficiency may lead to the intramitochondrial 
Figure 4
Brain lysine accumulation, ketotic hypoglycemia, and increased glutaric acid levels correlate with age-dependent susceptibility to brain injury in 
weanling Gcdh–/– mice. (A) Serum lysine, brain lysine, and brain glutaric acid levels, (B) serum and brain arginine and alanine levels, and (C) 
serum glucose (Glc) and β-hydroxybutyrate levels in weanling (4w) and adult (8w) Gcdh–/– mice (G–/–) and heterozygous controls (G–/+) on normal 
(ND) or lysine (Lys) diets. Amino acid differences are compared with heterozygous normal diet controls, and brain glutaric acid differences are 
compared with weanling Gcdh–/– normal diet controls. Mean ± SEM, *P < 0.01; **P < 0.001. n = 6 each group. (D) Twelve-day survival of adult 
(black circles, n = 20) and weanling (black diamonds, n = 20) Gcdh–/– mice on the lysine diet. (E) T2 maps (top) and T2-weighted images (bottom) 
of weanling Gcdh–/– mice. Color bar indicates T2 values (right side). Weanlings showed brain swelling, indicated by obliterated ventricles (black 
arrows; compare left with middle and right), and increased subdural fluid collection (red arrows, middle) at 48 hours of lysine diet exposure. At 6 
days, surviving weanlings developed striatal lesions indicated by increased T2 signal (red arrows, right).
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accumulation of glutaryl-CoA, which may result in sequestration 
of intramitochondrial free CoA. Alternatively, increased ketone 
body utilization leads to acetyl-CoA accumulation, which can also 
reduce free CoA levels (17, 18). Therefore, we measured acetyl-CoA, 
glutaryl-CoA, free CoA, ATP, phosphocreatine, and α-ketoglutarate 
in the brain of weanling and adult Gcdh–/– mice or heterozygote con-
trols with normal and lysine diet exposure (Figure 5, A–D). Hetero-
zygote controls on the lysine diet did not accumulate glutaryl-CoA 
but did show a 2-fold increase in acetyl-CoA (P < 0.01), indicating 
increased ketone body utilization consistent with the increased 
serum β-hydroxybutyrate levels in this group (Figure 5B). Weanling 
Gcdh–/– mice showed severe depletion of free CoA to 0.6% of normal 
(P < 0.001) on the lysine diet. However, glutaryl-CoA was unexpect-
edly reduced (P < 0.02), and acetyl-CoA was shown to accumulate 
to more than 10-fold normal diet levels (P < 0.02) (Figure 5, A and 
B). On the other hand, adult Gcdh–/– mice showed a 2-fold increase 
in glutaryl-CoA (P < 0.02) and a 5-fold increase in acetyl-CoA 
(P < 0.05) with depletion of free CoA to 38% of normal (P < 0.001) 
on the lysine diet (Figure 5B). Cortical ATP (P < 0.04) and phos-
phocreatine (P < 0.02) levels were depleted with lysine diet exposure 
only in weanling Gcdh–/– mice (Figure 5C). Whole-brain α-ketoglu-
tarate levels were depleted to 3% of normal (P < 0.001) in weanling 
Gcdh–/– mice on the lysine diet, consistent with reduced ATP levels 
and Krebs cycle disruption (Figure 5C). Adult Gcdh–/– mice showed 
α-ketoglutarate levels reduced to 46% of normal (P < 0.01) but no 
significant deficit in ATP or phosphocreatine (Figure 5C).
Increased ketone body utilization was previously shown to 
sequester free CoA and cause accumulation of α-ketoglutarate, 
since free CoA is a limiting substrate for α-ketoglutarate dehydro-
genase (17). Depletion of α-ketoglutarate with acetyl-CoA accu-
mulation in Gcdh–/– mice suggests a different mechanism, involv-
ing glutaric acid accumulation and resulting in CoA sequestration. 
We propose that loss of Krebs cycle intermediates through α-keto-
glutarate may be a primary cause of mitochondrial disruption as 
diagrammed in Figure 6. Accumulation of saccharopine, previ-
ously reported in human GA-I (8), may sequester α-ketoglutarate 
directly. Alternatively, glutaric acid accumulation may deplete 
Krebs cycle intermediates through exchange with α-ketogluta-
rate (Figure 6). Loss of Krebs cycle intermediates would prevent 
the regeneration of oxaloacetate, which is needed to combine with 
acetyl-CoA to form citrate for continued Krebs cycle function. The 
resulting accumulation of acetyl-CoA depletes available free CoA 
and depresses the buildup of glutaryl-CoA due to the limited mito-
chondrial CoA pool.
Since α-ketoglutarate is a precursor of glutamate synthesis 
(19) and the product of glutamate dehydration (20), depletion of 
α-ketoglutarate suggests that glutamate may be depleted as well. 
Additionally, GABA is produced from glutamate decarboxylation 
and was previously shown to be depleted in human GA-I (21). 
Therefore we compared glutamate, glutamine, and GABA levels 
in the brain of weanling Gcdh–/– mice with and without lysine diet 
exposure (Figure 5D). Glutamate and GABA levels were depleted 
Figure 5
Age-dependent brain biochemical changes with lysine diet exposure. (A) Chromatogram of acyl-CoA esters from brain extract of weanling 
Gcdh–/– mice on normal or lysine diet shows large accumulation of acetyl-CoA (†) and depletion of free CoA (‡) after 48 hours of lysine diet. 
Abs, absorbance. (B) Free CoA, acetyl-CoA, and glutaryl-CoA changes in brain extract of weanling and adult Gcdh–/– mice and heterozygous 
controls on normal or lysine diets. Mean ± SEM, *P < 0.01; **P < 0.001. n = 6 each group. (C) ATP, phosphocreatine (PCr), and α-ketoglutarate 
changes in cortex of weanling and adult Gcdh–/– mice and heterozygous controls on the lysine diet compared with normal diet. Mean ± SEM, 
§P < 0.04; ¶P < 0.02. n = 4 each group. (D) Glutamate, glutamine, and GABA levels in weanling and adult Gcdh–/– mice and heterozygous controls 
on the lysine diet compared with normal diet. Mean ± SEM. n = 6 each group.
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 117   Number 11   November 2007 3263
to half the normal concentrations (P < 0.001) after lysine diet expo-
sure while glutamine levels were reduced by only 24% (P < 0.01) 
(Figure 5D). Since glutamine is exclusively produced in glia (22), 
depletion of more glutamate than glutamine in this model sug-
gests a neuronal origin of metabolic impairment. GABA depletion 
may be responsible for the seizures observed in children and mice 
with Gcdh deficiency (7, 12).
Limiting brain lysine uptake and catabolism provides successful treat-
ment. The increase in brain lysine and glutaric acid associated with 
susceptibility in weanling Gcdh–/– mice suggested the possibility 
that (a) blocking brain lysine uptake or (b) reducing brain lysine 
catabolism may be protective. We tested the first possibility by 
administration of homoarginine, previously shown to effectively 
compete with brain lysine uptake (23). We tested the second pos-
sibility by administration of glucose to reduce lysine catabolism. 
We administered these treatments separately or combined to 
weanling Gcdh–/– mice on the lysine diet and monitored these ani-
mals for survival, biochemical changes, and brain injury by MRI 
(Figures 7 and 8). Each treatment substantially reduced brain glu-
taric acid accumulation, improved survival, and prevented brain 
injury in surviving animals at 6 days (Figure 7) although mildly 
increased transverse relaxation time constant (T2) values, repre-
senting vasogenic edema (24), were found in the striatum of some 
glucose-only treated mice (Figure 7F). Glucose treatment reduced 
accumulation of brain lysine by one-third (P < 0.03) and glutaric 
acid by 45% (P < 0.001), resulting in a 3-fold increase in 12-day 
survival (Figure 7, A and D). Homoarginine treatment reduced 
brain lysine accumulation by 50% (P < 0.01), resulting in 59% less 
glutaric acid accumulation (P < 0.001) and a 4-fold increase in 
12-day survival (Figure 7, B and D). Combined homoarginine/
glucose treatment provided similar control of lysine and glutaric 
acid compared with homoarginine alone but improved 12-day 
survival to 100% (Figure 7, C and D).
Treatment success correlated directly with control of brain 
glutaric acid levels and maintenance of glutamate and GABA. 
Glutamate and GABA levels were higher with glucose treatment 
compared with lysine diet controls (Figure 8A). However, homoar-
ginine alone and combined treatment maintained glutamate and 
GABA levels closest to normal (Figure 8A). Glutamine levels were 
further reduced with each treatment (P < 0.01) (Figure 8A). Glu-
cose and homoarginine treatment each protected free CoA, gluta-
ryl-CoA, and α-ketoglutarate levels (P < 0.01) although only com-
bined treatment decreased acetyl-CoA accumulation (P < 0.01), 
which resulted in substantially higher levels of free CoA compared 
with either treatment alone (Figure 8B). These effects are consis-
tent with protection of Krebs cycle function.
The protection of free CoA with combined treatment suggested 
that carnitine supplementation, routinely used to treat human 
GA-I (2), may be protective in this mouse model. However, carni-
tine supplementation at up to 4 times the level given to children 
during encephalopathic crisis (100 mg/kg every 6 hours) (5) did 
not provide any improvement in survival. The lack of benefit from 
carnitine in this model may be related to limited access of dietary 
supplementation (25, 26) or a limited ability to conjugate gluta-
rate in the brain as previously suggested (14).
Glutamate, glutamine, and GABA levels measured by 1H NMR 
spectroscopy provide a diagnostic marker. Serum glutaric acid lev-
els do not correlate with risk or progression of brain injury 
in human GA-I (11). Our current and previous data with this 
mouse model indicate that brain glutaric acid levels correlate 
with injury (12). However, brain glutaric acid levels currently 
cannot be monitored noninvasively and a clinical marker is 
needed to help guide treatment efforts (27). Glutamate and 
GABA depletion are shown here to correlate with elevated brain 
glutaric acid levels and progression of injury. The magnitude 
of glutamate and GABA depletion detected in brain extracts 
suggested that this biochemical change may be detectable by 
proton nuclear magnetic resonance (1H NMR) spectroscopy 
and used as a diagnostic marker. Therefore, we performed 1H 
NMR spectroscopy and MRI to correlate progression of enceph-
alopathy with glutamate and GABA levels (Figure 9). Weanling 
Gcdh–/– mice showed worsening symptoms associated with pro-
gression of encephalopathy between 48 and 60 hours of lysine 
diet exposure. A substantial reduction in the glutamate and 
Figure 6
Proposed mechanism of mitochondrial dysfunction. Normal 
mitochondrial metabolism involves lysine uptake through 
the ornithine carrier (ORC1) with proton exchange. Lysine 
degradation is initiated by combination with α-ketoglutarate 
(α-KG) to form saccharopine. Dehydrogenation of saccharo-
pine forms glutamate and aminoadipic semialdehyde, which 
is further oxidized to α-ketoadipate. Glutaryl-CoA is then 
formed from oxidation of α-ketoadipate with addition of free 
CoA. GCDH is required for complete oxidation with the for-
mation of acetyl-CoA that can enter the Krebs cycle. GCDH 
deficiency results in disruption of normal lysine breakdown, 
which may cause saccharopine to accumulate and sequester 
α-KG. Alternatively, accumulating free glutaric acid (gluta-
rate) may deplete α-KG levels by a strict counter-exchange 
mechanism via the oxodicarboxylate carrier (ODC) and to a 
lesser extent through the oxoglutarate carrier (OGC) that nor-
mally functions in the malate/aspartate shuttle. Depletion of 
α-KG prevents regeneration of oxaloacetate (OAA) needed to 
combine with acetyl-CoA to form citrate for continued Krebs 
cycle function. Acetyl-CoA is unable to enter the Krebs cycle 
and accumulates. CPTII, carnitine palmitoyltransferase II; 
PDH, pyruvate dehydrogenase.
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glutamine/creatine (Glx/Cr) ratio (P < 0.03) and the GABA/Cr 
ratio (P < 0.05) but not the N-acetyl aspartate (NAA)/Cr ratio 
was detectable by 1H NMR spectroscopy after 48 hours of lysine 
diet exposure (Figure 9, A and B). These changes are consis-
tent with our data from brain extracts (Figure 5D) and further 
show that glutamate and GABA depletion precede substantial 
neuronal damage, detected by a decrease in the NAA/Cr ratio as 
previously shown in human GA-I (28). Additionally, Glx/Cr and 
GABA/Cr ratios were higher with homoarginine (P < 0.01) and 
combined treatment (P < 0.01) but not glucose alone (Figure 
9B). These data are consistent with glutamate and GABA levels 
from brain extracts in treated compared with untreated controls 
(Figure 8A) and suggest that 1H NMR spectroscopy may be used 
to indicate impending brain injury.
Discussion
In this work we present several lines of evidence to suggest that 
the brain injury of GA-I involves mitochondrial disruption pre-
cipitated by glutaric acid production in the neuronal compart-
ment from available lysine. Consistent with initial neuronal injury, 
expression of Gcdh and the first enzyme in lysine degradation, lysine-
oxoglutarate reductase (29), are both limited to neurons. These data 
implicate the neuronal compartment as the predominant location 
of lysine catabolism and glutaric acid production in the brain. 
Intracellular glutaric acid accumulation may cause direct mito-
chondrial toxicity within neurons. Previous studies with isolated 
mitochondria showed swelling induced with 500–1,000 μM glutar-
ic acid (30). Higher concentrations of glutaric acid are consistently 
found in the brains of Gcdh–/– mice (12) and GA-I patients associated 
Figure 7
Glucose and homoarginine treatments increased survival and reduced brain injury in weanling Gcdh–/– mice on the lysine diet. Twelve-day 
survival of weanling Gcdh–/– mice on the lysine diet alone (black diamonds, n = 30) or mice treated (black squares) with glucose (A, n = 30), 
homoarginine (HA) (B, n = 30), or combined glucose and homoarginine (C, n = 30). (D) Serum lysine, brain lysine, and brain glutaric acid levels 
and (E) serum glucose and β-hydroxybutyrate levels in weanling Gcdh–/– mice on the lysine diet with glucose, homoarginine, or both for 48 hours 
compared with lysine diet alone. Mean ± SEM, *P < 0.01; **P < 0.001. n = 6 each group. (F) T2 maps (top) and T2-weighted images (bottom) of 
weanling Gcdh–/– mice with indicated treatments for 6 days show mild brain injury development in those treated with glucose alone (red arrow). 
Color bar indicates different T2 values (right side).
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with injury (6). In the current study, mitochondrial swelling and 
biochemical changes consistent with Krebs cycle disruption were 
observed when brain glutaric acid levels reached more than 1,000 
μM. Glutaric acid is a preferred substrate for the mitochondrial 
oxodicarboxylate carrier that normally exchanges α-ketoadipate 
for α-ketoglutarate in a strict counter-exchange mechanism (31). 
The level of glutaric acid accumulation, depletion of α-ketogluta-
rate, and accumulation of acetyl-CoA are all consistent with disrup-
tion of Krebs cycle function through loss of cycle intermediates as 
diagrammed in Figure 6.
Previous studies have shown a developmental change in BBB 
transport kinetics for basic and neutral amino acids that switch 
from low affinity/high capacity in the immature brain to high 
affinity/low capacity with maturity (15). Consistent with our cur-
rent findings, this developmental difference was previously shown 
to provide a 3- to 4-fold decrease in brain lysine influx between 
suckling and adult rats (32). High-capacity amino acid uptake in 
the immature brain supports the increased metabolic demand and 
protein turnover during rapid growth and myelination of the brain. 
However, this enhanced influx of amino acids also provides age-
dependent susceptibility to GA-I and other metabolic disorders. 
The immature brain readily uses alternate energy substrates such 
as ketone bodies, which may be supplied to the brain as ketogenic 
amino acids (i.e., lysine and branched-chain amino acids). Ketogenic 
amino acids have been shown to provide a substantial proportion 
of ketone bodies used for myelin synthesis (33). As brain growth 
and myelination are completed, metabolic demands are reduced 
and the brain uses glucose more exclusively (15). Accordingly, 
transport and catabolic enzyme activity for lysine are reduced in the 
brain with maturity (32, 34). Therefore the immature brain is espe-
cially susceptible to metabolic disorders of amino acid metabolism 
such as GA-I and maple syrup urine disease (35). This susceptibil-
ity is typically realized in the context of catabolic stress associated 
with fasting during a nonspecific illness. Catabolic stress leads to 
breakdown of muscle protein to free amino acids and enhanced 
amino acid uptake and turnover in the liver for gluconeogenesis 
(16). Hypoglycemia in children with GA-I during metabolic crisis 
(8) and in Gcdh–/– mice on a lysine diet suggests that the process of 
gluconeogenesis from available amino acids is impaired. Decreased 
glucose levels place greater dependence on ketone bodies and keto-
genic amino acids in the brain. The combination of catabolic stress 
and enhanced amino acid access to the immature brain provides 
the opportunity for large accumulations of aberrant metabolites 
in GA-I and other disorders of amino acid metabolism. These age-
dependent susceptibilities, related to GA-I, and the proposed effect 
of treatments are diagrammed in Figure 10.
Recent evidence shows that glutaric acid has limited BBB per-
meability, suggesting de novo synthesis rather than diffusion or 
transport of glutaric acid into the brain (14). To confirm that glu-
taric acid is produced in the brain de novo from available lysine, 
we demonstrated that blocking brain lysine uptake with homoar-
ginine decreased glutaric acid levels, resulting in reduced brain 
injury and increased survival. These findings are likely to have 
clinical relevance, since elevated brain glutaric acid levels and brain 
injury in GA-I patients occur despite the use of low lysine diets (4, 
7). In the present study, controlling brain glutaric acid levels with 
homoarginine and glucose prevented encephalopathy, underscor-
ing the importance of this strategy for treatment.
Currently, there is no reliable marker that can be used nonin-
vasively for predicting the risk of brain injury in human GA-I. 
Figure 8
Glucose and homoarginine decrease biochemical changes associated with lysine diet exposure. (A) Glutamate, glutamine, and GABA levels 
with indicated treatments in weanling Gcdh–/– mice compared with lysine diet alone at 48 hours. Mean ± SEM, *P < 0.01; **P < 0.001. n = 6 
each group. (B) Free CoA, acetyl-CoA, glutaryl-CoA, and α-ketoglutarate levels in weanlings with indicated treatments compared with lysine 
diet alone. Mean ± SEM. n = 6 each group.
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Brain glutaric acid levels were previously shown to correlate with 
injury in this mouse model (12) but currently cannot be measured 
noninvasively. Glutamate and GABA depletion monitored by 1H 
NMR spectroscopy correlates with increased brain glutaric acid 
levels and may translate for use in human GA-I to detect risk of 
brain injury. Glutamate depletion in this mouse model is consis-
tent with reduced brain glucose utilization, as previously shown 
with immature rats (36). Reduced brain glucose utilization was 
previously shown in human GA-I using 18fluoro-2-deoxyglucose 
uptake studies (37), indicating that glutamate levels may also be 
compromised in human GA-I with encephalopathy. Glutamate 
is the precursor for GABA (38), and reduced GABA levels in this 
mouse model and human GA-I (7) correlate with glutamate deple-
tion and further indicate that glutamate levels may be compro-
mised in human GA-I. GABA levels may be initially reduced along 
with glutamate as brain glucose utilization is compromised dur-
ing encephalopathy (37). Glutaric acid accumulation suppresses 
GABA production (21), and the return of glutamate levels with 
restored brain glucose utilization may set up unopposed excitatory 
neurotransmission resulting in seizures and excitotoxic lesions 
found in this model and in human GA-I (9). This possibility may 
explain the differences between glucose and homoarginine treat-
ments and emphasizes the importance of controlling brain glu-
taric acid accumulation for neuroprotection.
Establishment of this mouse model provides the opportunity 
to test the effects of current and novel treatment strategies. Intra-
venous glucose administration is standard treatment for GA-I 
encephalopathy, but there are currently no data on the effect of 
this treatment in the brain. The lysine diet induces a catabolic 
state in Gcdh–/– mice similar to that seen in children with GA-I 
during crisis, including hypoglycemia and ketosis (Figure 4C). 
Catabolic stress leads to increased amino acid accumulation and 
breakdown in the liver (16). For lysine, increased catabolism was 
shown to be regulated by mitochondrial influx (39), and glucose 
availability reduces this effect (39, 40). We propose that a similar 
mechanism regulates lysine utilization in the immature brain. In 
the context of catabolic stress with reduced serum glucose lev-
els, the immature brain depends on alternate energy substrates 
such as ketone bodies and ketogenic amino acids. Glucose sup-
plementation provides adequate preferred substrate and reduces 
the demand for alternate substrates. This reduced demand corre-
lates with reduced brain lysine accumulation in adult brains that 
Figure 9
Glx and GABA depletion detected by 1H NMR spectroscopy correlates with treatment success. (A) Comparison of 1H NMR spectra from wean-
ling Gcdh–/– mice on a normal (left) or lysine diet (middle) or with combined glucose/homoarginine treatment (right) indicates a large decrease 
in the Glx peak (red arrow, center) and a smaller decrease in NAA after 48 hours of lysine diet exposure that was prevented by combined 
treatment (right). Multiple resonance peaks for GABA are not indicated. (B) Glx/Cr ratio, GABA/Cr ratio, and NAA/Cr ratio detected by 1H NMR 
spectroscopy in weanling Gcdh–/– mice on the lysine diet or with indicated treatments. Data are reported as percentage of normal diet control. 
Mean ± SEM, *P < 0.03. n = 4 per group. Lower left panel indicates voxel location used to acquire NMR spectroscopy data.
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utilize	glucose more exclusively (15). Here we demonstrate that 
dietary glucose therapy reduced lysine catabolism (glutaric acid 
formation) more than lysine accumulation in the brain. Serum 
glutaric acid levels were also lower with glucose treatment (data 
not shown), consistent with the influence of glucose to reduce 
amino acid turnover in the liver (41).
Combined homoarginine and glucose treatment may provide 
the best protection by reducing the substrate and the drive for 
glutaric acid production. However, the lack of cumulative effect 
on glutaric acid levels suggests that each treatment affects a dif-
ferent part of the same pathway. Glutaric acid is produced from 
lysine breakdown in the context of GCDH deficiency. The rate-
limiting step of lysine breakdown at the mitochondrial level was 
shown to be lysine influx, which was increased by a high-protein 
diet and reduced by glucose availability (39). Our current data sup-
port a model in which lysine access is limited by homoarginine at 
the BBB and by glucose at the mitochondrial level. Both glucose 
and homoarginine reduced lysine breakdown (glutaric acid for-
mation) similarly, but brain lysine accumulation remained higher 
with glucose treatment compared with homoarginine. Therefore, 
both treatments reduce brain glutaric acid production by limiting 
lysine access, although to different compartments.
Similar to Huntington disease, the expression of the affected 
gene in GA-I is not specific to the striatum but results in selec-
tive striatal degeneration. Medium spiny neurons are primarily 
affected in both disorders (4, 10). Although the clinical presenta-
tion of GA-I is commonly associated with acute onset, the result-
ing neuropathology in this mouse model is strikingly similar to 
that of Huntington disease, including the involvement of cortical 
pyramidal neurons (12, 42). Corticostriatal circuitry may play a 
role in the pathophysiology of both disorders (43). Further study 
of this mouse model may reveal factors underlying striatal-specific 
susceptibility that can be used to develop protective strategies.
The current findings provide insight into the age-dependent 
mechanism, treatment, and monitoring of GA-I and offer new 
strategies for the prediction and prevention of brain injury. 
Enhanced amino acid accumulation in the immature brain may 
contribute to the age-dependent susceptibility in other neuromet-
abolic disorders (44). Competitive transport inhibition, shown in 
this study using homoarginine, provides an attractive approach to 
developing potential treatments for these disorders.
Methods
Materials. All chemicals were purchased from Sigma-Aldrich unless other-
wise specified.
Animals. All animal experiments were approved by the Pennsylvania State 
University College of Medicine Institutional Animal Care and Use Commit-
tee. Gcdh–/– mice and age-matched WT controls, both of mixed C57Bl/6J × 
129SvEv background (45), were generated from homozygotes maintained 
at Penn State College of Medicine (Department of Comparative Medicine) 
in accordance with Institutional Animal Care and Use Committee research 
guidelines set forth by Pennsylvania State University and the Society for 
Neuroscience policy on the use of animals in neuroscience research. Het-
erozygotes (Gcdh–/+) were generated by mating Gcdh–/– and WT mice. Gcdh–/– 
mice were previously produced by replacement of the first 7 exons of Gcdh 
with an in-frame β-gal cassette including a nuclear localization sequence. 
Therefore, Gcdh–/+ and Gcdh–/– mice express β-gal under the control of the 
Gcdh regulatory elements (45). To detect expression of β-gal, we used hetero-
zygotes to avoid loss of cells that require GCDH during development.
Special diets. Diets were purchased from Harland Teklad. The normal diet 
was the Harland Teklad 2018 diet, which is 18% protein. The high-protein 
diet	(TD.03637) (70% casein) contained 62% protein, which is 4.7% lysine 
by weight. The lysine diet (TD.04412) was prepared by adding free lysine to 
a standard diet to achieve 4.7% total lysine. This level of lysine is not toxic 
in normal animals (46, 47). The lysine-homoarginine diet was prepared 
by adding 5% homoarginine to the lysine diet. Glucose was administered 
by adding 5% glucose monohydrate by weight to water and provided ad 
libitum. For intervention studies, male and female Gcdh–/– mice were placed 
on special diets at 4 weeks of age, housed 2 per cage, and observed every 12 
hours; mice and diets were weighed daily (n = 30 for each study group). All 
special diet–treated animals and corresponding controls were evaluated 
daily for symptoms as previously described (12).
Neuropathology. To follow the earliest pathologic events, 12 Gcdh–/–, 5 
Gcdh–/+, and 5 WT mice were placed on a high-protein diet at 4 weeks of 
Figure 10
Proposed mechanism of susceptibility and effect of treatment. 
Increased lysine accumulation associated with the catabolic state of 
fasting illness or lysine loading results in accumulation of glutaric acid 
in the context of GCDH deficiency. Increased glutarate accumulation 
in the brain and liver leads to Krebs cycle inhibition as proposed in 
Figure 6. In the liver, Krebs cycle inhibition leads to inhibition of gluco-
neogenesis resulting in hypoglycemia. Hypoglycemia stimulates the 
use of alternate energy substrates in the brain including ketone bod-
ies and ketogenic amino acids. Increased brain lysine utilization leads 
to enhanced glutarate accumulation and Krebs cycle inhibition. Krebs 
cycle inhibition in the brain results in depletion of glutamate, GABA, 
and ATP, with subsequent neuronal injury. Homoarginine blocks 
brain lysine uptake and controls glutarate accumulation from the sub-
strate level. Glucose supplementation prevents hypoglycemia and the 
demand for ketone bodies and ketogenic amino acids.
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age. Two 4-week-old Gcdh–/–, Gcdh–/+, and WT mice were sacrificed before 
starting the diet (0 hour control), and 2 more Gcdh–/– mice were sacrificed 
every 12 hours after starting the diet and processed for electron micros-
copy. Three remaining Gcdh–/+ and WT mice were sacrificed 60 hours after 
starting the diet and processed for electron microscopy. A second group of 
12 Gcdh–/–, Gcdh–/+, and WT mice at 4 weeks of age were placed on the lysine 
diet. Three Gcdh–/–, Gcdh–/+, and WT mice were sacrificed every 12 hours and 
processed for histology.
For histology, mice were anesthetized with 100 mg/kg pentobarbital (i.p.), 
perfused with lactated Ringers (Baxter) followed by 4% paraformaldehyde 
for 15 minutes. Brains were postfixed in 4% paraformaldehyde for 48 hours 
and paraffin embedded. For electron microscopy, mice were perfused with 
4% paraformaldehyde with 1% glutaraldehyde in 0.2 M cacodylate buf-
fer. Brains were removed and postfixed for 48 hours and transferred to 
perfusion buffer until processed.
Histology. H&E slides were prepared from paraffin-embedded brains. 
Sequential 10-μm thick coronal brain slices were made within 0.5 mm of 
the bregma line for striatal sections and between bregma –1.5 and –2.0 for 
hippocampal sections (48).
Electron microscopy. Brains were dissected into coronal, hippocampal, or 
striatal blocks. Toluidine blue–stained semithin sections 1-μm thick were 
made from these blocks. Ultrathin sections of 90 nm were then cut from 
the same blocks and stained with uranyl acetate and lead citrate for trans-
mission electron microscopic analysis using a Philips CM10 transmission 
electron microscope.
Immunohistochemistry and confocal microscopy. GFAP, β-gal, neuron-specific 
nuclear protein (NeuN), neurofilament (N52), occludin (Occl), and choline 
acetyltransferase (ChaT) were detected using deparaffinized 10-μm–thick 
coronal brain slices. For β-gal colocalization, tissue was blocked with 
normal serum and incubated with monoclonal α-GFAP (1:500) (Sigma-
Aldrich), monoclonal α-NeuN (1:20) (Millipore), or monoclonal α-Occl 
(1-200) (Invitrogen) at the same time as with polyclonal α-β–gal (1:200) 
(Millipore). Additional slides were incubated with polyclonal α-GFAP 
(1:500) (Dako) and monoclonal α-N52 (1-200) (Sigma-Aldrich) at the same 
time or polyclonal α-ChaT (1:200) (Millipore) alone. All incubations were 
in PBS with normal serum overnight at 4°C. The slides were washed sepa-
rately 3 times each in PBS and incubated with goat anti-rabbit IgG coupled 
to Cy2 for β-gal and goat anti-mouse IgG coupled to Cy3 for NeuN, Occl, 
ChaT, or monoclonal GFAP. Polyclonal GFAP was detected with goat anti-
rabbit coupled to Cy3, and N52 was detected with goat anti-mouse coupled 
to Cy2 (all secondary antibodies diluted 1:2,000; Jackson ImmunoResearch 
Laboratories Inc.). All slides were counterstained with DAPI, 0.1 μg/ml in 
PBS for 5 minutes. Confocal microscopy was performed using a Leica TCS 
SP2 AOBS confocal microscope (Leica Microsystems).
Biochemical analysis. Gcdh–/–, Gcdh–/+, and WT mice were placed on the nor-
mal or lysine diet at 4 and 8 weeks of age in groups of 6 (4 different groups 
by diet and age for each genotype). To detect differences in biochemical 
changes with intervention treatments, 4-week-old Gcdh–/– mice were placed 
on the lysine diet with 5% glucose added to the water (n = 6), or 5% homoar-
ginine added to the diet (n = 6), or both (n = 6) for 48 hours or 2 weeks (n = 6). 
Mice were anesthetized with 100 mg/kg pentobarbital (i.p.). Serum and 
brains were collected and frozen to –80°C. Brains were extracted with 8% 
perchloric acid (PCA) and neutralized with potassium hydroxide as previ-
ously described (49). All neutralized PCA extracts and serum samples were 
kept at –80°C until analysis.
Amino acids. Serum and brain amino acids were derivatized with phenyl 
isothiocyanate (PITC) and separated and quantified by reverse-phase high-
pressure liquid chromatography as previously described (50) using a C18 
Econosphere column (150 mm × 4.6 mm ID, 3 μm) from Alltech with nor-
leucine (100 μM) as an internal standard.
Glutaric acid and 3-OHGA. Serum samples and brain extracts were ana-
lyzed by gas chromatography–mass spectroscopy using stable-isotope 
dilution as previously described (51). Deuterium-labeled internal stan-
dards for GA (d4-GA) (0.05 mg/ml) and 3-OHGA (d5-HGA) (0.05 mg/ml) 
were added at 0.05 ml each to 0.5 ml serum samples or 1.5 ml brain 
homogenates. Sulfosalicylic acid at 0.15 ml of 9.33% or 70 mg was added 
to serum or brain samples, respectively. Samples were extracted twice with 
3 ml diethyl ether and 1.5 ml ethyl acetate. Combined organic phases were 
dried at 30°C under nitrogen and derivatized with 0.05 ml BTSFA/1% 
TMCS [N,O-Bis(trimethylsilyl)trifluoroacetamide with trimethylchlorosi-
lane] for 20 minutes at 80°C. Injected volume of 0.001 ml was analyzed 
using a Hewlett-Packard 6890 gas chromatograph with a 5973 mass spec-
trometer. The mass spectrometer monitored ions at 265/261 (with check 
of ratio at 237/233) for glutaric and 188/185 (check ratio at 262/259) for 
3-OHGA in separate runs.
ATP and phosphocreatine. Gcdh–/– and WT mice at 4 and 8 weeks of age were 
placed on the normal or lysine diet in groups of 4 (8 different groups by 
genotype, diet, and age). All mice were sacrificed by focused beam micro-
wave irradiation to preserve phosphorylation status as previously described 
(52). The cortex, hippocampus, and striatum were dissected from both 
sides of the brain from each mouse and frozen. Samples from each brain 
area were weighed and extracted with 8% PCA as described above and neu-
tralized. Neutralized PCA extracts were assayed for ATP and phosphocre-
atine enzymatically (49). ATP was measured by following the formation of 
NADPH spectrophotometrically using hexokinase coupled with glucose-
6-phosphate dehydrogenase in the presence of glucose and NADP+. Phos-
phocreatine was measured by adding Cr kinase to the above reaction and 
following the additional formation of NADPH. Protein concentrations 
were measured by the method of Lowry (53).
Coenzyme A, glutaryl-CoA and α-ketoglutarate. PCA extracts of brain sam-
ples from each group described above were used to analyze free reduced 
CoA and glutaryl-CoA by HPLC as previously described (54). For α-keto-
glutarate, brain extracts were extracted with ethyl acetate. Dried residues 
were reconstituted in 25 mM potassium phosphate buffer at pH 2.5. CoA, 
acetyl-CoA, glutaryl-CoA, and α-ketoglutarate standards were used to 
develop a curve for quantification.
MRI and H1 spectroscopy. MRI was performed on a 7.0 T Bruker system 
using a 2-mm birdcage coil at 48 hours, 72 hours, and 6 days following 
the start of special diets (n = 4 mice per diet group). Mice were anesthe-
tized with isoflurane (1–1.5%) and imaged with a T2-weighted multiecho, 
spin echo sequence (5 0.5 mm thick slices, TR/TE = 3,000/10.6-148.4 ms, 
14 echoes, 117 × 117 μm2 resolution, 2 averages; TR, repetition time; TE, 
echo time). T2 values were calculated on a pixel-by-pixel basis from the 
corresponding exponential fits using CCHIPS software (55). 1H NMR 
spectroscopy data were acquired between 48 and 72 hours, using PRESS 
sequence (TR/TE = 2656/7 ms, 512 averages, 4.2 ml voxel covering the 
cortex and the striatum; Figure 6A). NMR spectroscopy data was pro-
cessed using LCModel software (56). Data quality was assessed by visual 
inspection of the peaks in addition to quantitative measurement of the 
line width (full width as half maximum), automatically provided by 
LCModel software (56). Mean SD was greater than 20% for estimated 
concentration of reported metabolites. Mann-Whitney U test was used 
for statistical analysis. Data are presented as a ratio to Cr, with the 
assumption that its concentration was unaffected.
Statistics. Normally distributed data sets were analyzed by ANOVA with 
Fisher least-significant-difference post hoc test. Kruskal-Wallis 1-way 
ANOVA on ranks was performed with Student-Neuman-Keuls post hoc 
test on samples that were not normally distributed. SigmaStat software 
(Jandel Scientific) was used for analysis. All P values of less than 0.05 were 
considered statistically significant.
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